<DOC>
	<DOCNO>NCT03090724</DOCNO>
	<brief_summary>The purpose study assess effect age pharmacokinetic ( PK ) profile BIA 5-453 metabolite .</brief_summary>
	<brief_title>Pharmacokinetics BIA 5-453 Its Metabolites</brief_title>
	<detailed_description>Single-centre , open-label , parallel group , non-randomised study 12 healthy elderly 12 healthy young male subject , participate 2 consecutive phase : Phase A : single-dose phase ( include wash period ) ; Phase B : multiple-dose phase 7 day ( steady state ) .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>All subject ( young elderly ) : 1 . A signed date informed consent form studyspecific screen procedure perform . 2 . Healthy determine investigator basis medical history , physical examination , clinical laboratory test result , vital sign digital 12lead electrocardiogram ( ECG ) . 3 . Nonsmoker smoker &lt; 10 cigarette per day determine history . Must able abstain smoking inpatient stay . Young subject : 4 . Males age 18 45 year , inclusive . Elderly subject : 5 . Males old 65 year , inclusive . Specific inclusion criterion procedure : genotyping Since acetylation important BIA 5453 metabolic pathway , NAT1 NAT2 genotyping require inclusion distinguish poor faster acetylators ( could however enrol study ) . All subject ( young elderly ) : General 1 . Subjects participate clinical trial investigational drug within 90 day prior screen . 2 . Subjects likely noncompliant protocol , felt unsuitable Investigator reason . 3 . Positive serologic finding human immunodeficiency virus ( HIV ) antibody , hepatitis B surface antigen ( HBsAg ) , and/or hepatitis C virus ( HCV ) antibody . 4 . Positive finding urine drug screen ( amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine , methadone , opiates , MDMA [ 3,4methylenedioxymethamphetamine ; ecstasy ] ) . Medical History 5 . Any significant cardiovascular , hepatic , renal , respiratory ( e.g . childhood asthma ) , gastrointestinal , endocrine ( e.g . diabetes ) , immunological , dermatological , haematological , neurological , psychiatric disease history thereof . 6 . Acute disease state ( e.g. , nausea , vomit , fever , diarrhoea ) within 7 day study Day 1 . 7 . Subjects proned orthostatic hypotension : measurement supine blood pressure ( BP ) heart rate ( HR ) subject rest least 10 minute , follow stand BP HR 2 minute stand : orthostatic hypotension define difference supine systolic BP ( SBP ) stand SBP ≥20 mmHg difference supine diastolic BP ( DBP ) stand DBP ≥10 mmHg . 8 . History drug abuse within 1 year study day 1 . 9 . History alcoholism within 1 year day 1 . Consumption 50 g ethanol per day ( 12.5 cL glass 10° [ 10 % ] wine = 12 g ; 4 cL aperitif , 42° [ 42 % ] whiskey = 17 g ; 25 cL glass 3° [ 3 % ] beer = 7.5 g ; 25 cL glass 6° [ 6 % ] beer = 15 g. 10 . History clinically important drug allergy . 11 . Had previously receive BIA 5453 . Prohibited treatment dietary restriction 12 . Consumption caffeinecontaining product ( e.g. , coffee , tea , chocolate , soda ) excess 6 cup per day ( equivalent ) , grapefruit , grapefruitcontaining product , alcoholic beverage within 24 hour study day 1 . 13 . Use overthecounter drug include herbal supplement ( except occasional use acetaminophen [ paracetamol ] , aspirin vitamin ≤100 % recommend daily allowance ) within 7 day BIA 5453 administration . 14 . Donation blood ( i.e . 450 mL ) within 60 day study day 1 . Young subject : General 15 . An automatic QTc interval read ≥450 m screen assessment . Prohibited treatment dietary restriction 16 . Prohibited Treatments : use investigational drug within 90 day ( young elderly subject ) prescription drug within 30 day BIA 5453 administration . Elderly subject : General 17 . An automatic QTc interval read ≥470 m screen assessment .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>